NYSE:MRK
Merck & Co., Inc.
A premier global biopharmaceutical giant delivering high-value therapies in oncology and vaccines with consistent double-digit cash flow generation.
Key Metrics
Investment Thesis
Bull Case
Investors should consider MRK for its resilient cash flow generation, evidenced by $16.47B in operating cash flow and a substantial $14.56B cash balance providing flexibility for M&A or dividends. The diversified portfolio of high-value oncology drugs offers stable long-term growth prospects despite macroeconomic headwinds.
Bear Case
Concerns remain regarding the heavy capital intensity with $4.11B in capital expenditures and $27.89B in other investing outflows which could impact near-term earnings per share. Additionally, the company carries significant long-term debt of $46.75B, creating interest rate sensitivity and leverage risks during tightening financial conditions.
About Merck & Co., Inc.
Merck & Co., Inc. (MRK) is a global leader in healthcare research and development, serving markets worldwide with innovative medicines, vaccines, and animal health solutions. The company's recent performance highlights strong revenue growth to $65.01B in 2025, driven by its robust pipeline of oncology and immunology products.
Analysis
Management Discussion
Management delivered solid operational performance with operating profit of $21.07B and net income returning to $18.26B after a volatile 2023. The company successfully balanced heavy investing outflows of $13.74B for acquisitions and capex against robust operating cash flows exceeding $16B.
Industry Overview
The global pharmaceutical industry is characterized by intense competition for blockbuster drug launches, a heavy reliance on R&D innovation to replace expiring patents, and strict regulatory oversight from agencies like the FDA. Merck competes against giants like Pfizer and Roche in a landscape where intellectual property protection is paramount.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $59.28B | $60.12B | $64.17B | $65.01B |
| Cost of Revenue | $17.41B | $16.13B | $15.19B | $16.38B |
| Gross Profit | $41.87B | $43.99B | $48.98B | $48.63B |
| Operating Expenses | $25.43B | $42.10B | $29.04B | $27.56B |
| Operating Income | $16.44B | $1.89B | $19.94B | $21.07B |
| R&D | $13.55B | $30.53B | $17.94B | $15.79B |
| G&A | $10.04B | $10.50B | $10.82B | $10.73B |
| Stock-Based Comp | $541.0M | $645.0M | $761.0M | $820.0M |
| Depreciation | $1.82B | $1.83B | $2.10B | $3.04B |
| Amortization | $2.10B | $2.00B | $2.40B | $2.80B |
| Other OpEx | $1.84B | $1.06B | $285.0M | $1.04B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $962.0M | $1.15B | — | — |
| Interest Income | $157.0M | $365.0M | $415.0M | $343.0M |
| Pre-Tax Income | $16.44B | $1.89B | $19.94B | $21.07B |
| Income Tax | $1.92B | $1.51B | $2.80B | $2.80B |
| Continuing Ops | $14.53B | $377.0M | $17.13B | $18.26B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $14.52B | $365.0M | $17.13B | $18.26B |
| Minority Interest | $0 | $0 | $16.0M | $9.0M |
| Net to Common | $14.52B | $365.0M | $17.12B | $18.25B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $35.72B | $32.17B | $38.78B | $43.52B |
| Cash & Equivalents | $12.69B | $6.84B | $13.24B | $14.56B |
| Marketable Securities | $498.0M | $252.0M | $447.0M | $0 |
| Accounts Receivable | $9.45B | $10.35B | $10.28B | $11.78B |
| Inventory | $5.91B | $6.36B | $6.11B | $6.66B |
| Other Current Assets | $7.17B | $8.37B | $8.71B | $10.52B |
| Long-Term Assets | $73.44B | $74.51B | $78.32B | $93.35B |
| PP&E (Net) | $21.42B | $23.05B | $23.78B | $25.32B |
| Intangibles | $20.27B | $18.01B | $16.37B | $26.68B |
| Goodwill | $21.20B | $21.20B | $21.67B | $21.58B |
| Operating Leases | $1.35B | $1.44B | $1.37B | $1.51B |
| LT Securities | $1.01B | $252.0M | $463.0M | $956.0M |
| Other LT Assets | $8.18B | $10.56B | $14.67B | $17.31B |
| Total Assets | $109.16B | $106.67B | $117.11B | $136.87B |
| Current Liabilities | $24.24B | $25.69B | $28.42B | $28.33B |
| Accounts Payable | $4.26B | $3.92B | $4.08B | $4.40B |
| Current Debt | $1.70B | $1.30B | $2.50B | $2.30B |
| Current Leases | $281.0M | $285.0M | $282.0M | $294.0M |
| Taxes Payable | $1.99B | $2.65B | $3.91B | $4.73B |
| Other Current Liab | $14.12B | $15.55B | $15.56B | $14.46B |
| Long-Term Liabilities | $38.86B | $43.35B | $42.31B | $55.88B |
| Long-Term Debt | $28.75B | $33.68B | $34.46B | $46.75B |
| LT Operating Leases | $1.01B | $928.0M | $877.0M | $901.0M |
| Other LT Liab | $9.11B | $8.73B | $6.97B | $8.23B |
| Total Liabilities | $63.10B | $69.04B | $70.73B | $84.20B |
| Shareholders' Equity | $46.06B | $37.63B | $46.37B | $52.66B |
| Retained Earnings | $61.08B | $53.90B | $63.07B | $73.08B |
| AOCI | $-4.77B | $-5.16B | $-4.95B | $-4.29B |
| Total L&E | $109.16B | $106.67B | $117.11B | $136.87B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $14.52B | $365.0M | $17.13B | $18.26B |
| Non-Cash Adjustments | $2.80B | $6.29B | $3.01B | $-5.97B |
| Working Capital Changes | $1.77B | $6.35B | $1.32B | $4.18B |
| Cash from Operations | $19.09B | $13.01B | $21.47B | $16.47B |
| Capital Expenditures | — | $3.86B | $3.37B | $4.11B |
| Cash from Investing | $-4.96B | $-14.08B | $-7.73B | $-13.74B |
| Debt Issuances | $0 | $5.94B | — | — |
| Debt Repayments | $2.25B | $1.75B | $1.29B | $2.50B |
| Share Buybacks | $0 | $1.35B | $1.31B | $5.08B |
| Dividends Paid | $7.01B | $7.45B | $7.84B | $8.18B |
| Cash from Financing | $-9.12B | $-4.81B | $-7.03B | $-1.92B |
| FX Effect | $-410.0M | $23.0M | $-293.0M | $563.0M |
| Net Change in Cash | $4.61B | $-5.86B | $6.41B | $1.37B |
| Beginning Cash | $8.17B | $12.77B | $6.91B | $13.32B |
| Ending Cash | $12.77B | $6.91B | $13.32B | $14.69B |
Frequently Asked Questions
How does Merck & Co., Inc. make money?
The company generates revenue primarily through three core segments: Human Health (including Oncology, Vaccines, Immunology, and Cardiology), Animal Health (veterinary pharmaceuticals and diagnostics), and Specialty Medical Devices.
What are the main risks for MRK?
Significant regulatory hurdles for new drug approvals, potential patent cliffs on existing blockbusters reducing future revenue, high volatility in clinical trial outcomes, and geopolitical supply chain disruptions affecting manufacturing.
What is MRK's competitive advantage?
Merck possesses a deep pipeline of differentiated blockbuster drugs in oncology and vaccines, a massive R&D investment of $15.79B fostering innovation, and a diverse geographic footprint that mitigates regional market risks.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.